Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.41 |
| ▸ | CES1 | P23141 | 8/20 | 0.39 |
| ▸ | CES2 | O00748 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PLOD2 | O00469 | 3/20 | 0.39 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.38 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77034 | 1.00 | FAAH (0.41) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL8070156 | 1.00 | FAAH (0.41) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL93393 | 0.85 | KMT2A (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL183178 | 0.85 | PLOD2 (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL4837194 | 0.85 | KMT2A (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL23009373 | 0.83 | PLOD2 (0.43) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL11515923 | 0.83 | FAAH (0.41) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL11974568 | 0.83 | KMT2A (0.32) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL23176761 | 0.83 | KMT2A (0.32) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL9566006 | 0.82 | KMT2A (0.37) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-6677410-B2 | COORDINATION CATALYSTS | EASTMAN CHEMICAL COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030004285-A1 | Procatalysts, catalyst systems, and use in olefin polymerization | WESTLAKE LONGVIEW CORPORATION | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | FAAH 4765/4885CES1 4792/4885CES2 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.